Market Research Report
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 188.8.131.52) - Drugs in Development, 2021
|Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 184.108.40.206) - Drugs in Development, 2021|
Published: March 31, 2021
Global Markets Direct
Content info: 32 Pages
Delivery time: 1-2 business days
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 220.127.116.11) - Protein kinase C theta (PKC-θ) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-costimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway.
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 18.104.22.168) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology and Metabolic Disorders which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Breast Cancer, Ewing Sarcoma, Heart Transplant Rejection, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Obesity, Prostate Cancer and Type 2 Diabetes.
The latest report Protein Kinase C Theta Type - Drugs in Development, 2021, outlays comprehensive information on the Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 22.214.171.124) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 126.96.36.199) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.